“We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments for patients,” said John Montana, executive director, Integrated Drug Discovery at Charles River. “Our long-term collaboration with Genentech has been mutually beneficial for both companies. As our teams have demonstrated, when biotechs and CROs work together, they have the ability to enhance innovations in early discovery research.”
Through this alliance, Charles River provides Genentech early discovery services, including medicinal chemistry, in vitro and in vivobiology, structural biology, and computer-aided drug design, to help identify promising candidates for preclinical development.
Charles River and Genentech have engaged in an ongoing program since 2005, with the latest extension providing a three-year continuation. The program began with a single project involving medicinal chemistry, and has evolved over the past 11 years to a multi-disciplinary collaboration drawing on Charles River’s leading researchers in chemistry, biology and pharmacology.